USO 23164
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (CB10A)
Disease Types: CAR-T
Eligibility Requirements:
• Histologically confirmed aggressive B-cell NHL
• DLBCL NOS, HGBL, transformed DLBCL from FL or
MZL, and PMBCL
• Documented CD19+ disease
• CD19 exposed patients only; documentation not
required for CD19 naïve patients
• ECOG status 0 or 1
• Prior systemic therapy (1 prior line) should include:
• An anti-CD20 antibody and an anthracycline.
• Relapsed or refractory disease
• Anti-CD19 targeting agent (CD19 relapsed cohort only)
• Donor HLA matching of ≥ 4 alleles with absence of DSA
• Subjects with active acute or chronic GvHD requiring therapy
are excluded
• Subjects with prior allogenic stem cell transplant are excluded
For more information on this trial CLICK HERE .
Available at: